Hyperphosphatemic Tumoral Calcinosis With Pemigatinib Use

BACKGROUND/OBJECTIVE: Pemigatinib, a fibroblast growth factor receptor (FGFR) 1-3 inhibitor, is a novel therapeutic approach for treating cholangiocarcinoma when an FGFR fusion or gene rearrangement is identified. Although the most reported side effect of pemigatinib is hyperphosphatemia, tumoral ca...

Descripción completa

Detalles Bibliográficos
Autores principales: Puar, Akshan, Donegan, Diane, Helft, Paul, Kuhar, Matthew, Webster, Jonathan, Rao, Megana, Econs, Michael
Formato: Online Artículo Texto
Lenguaje:English
Publicado: American Association of Clinical Endocrinology 2022
Materias:
Case Report
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9508588/
https://www.ncbi.nlm.nih.gov/pubmed/36189136
http://dx.doi.org/10.1016/j.aace.2022.07.001

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9508588/
https://www.ncbi.nlm.nih.gov/pubmed/36189136
http://dx.doi.org/10.1016/j.aace.2022.07.001

Ejemplares similares